Alendronate Therapy and Renal Insufficiency: A Prescription for Problems?
Federal Practitioner. 2006 July;23(7):17
July 1, 2006|Federal Practitioner
Author and Disclosure Information
Although little research has been published on the use of bisphosphonates in patients with severe renal insufficiency, the FDA advises against administering these drugs to such patients for theoretical reasons. Now, a retrospective pilot study challenges the long held notion that reduced renal clearance of alendronate increases adverse drug events.
